Drugs / DIHOMO-GAMMA-LINOLENIC ACID
DIHOMO-GAMMA-LINOLENIC ACID
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03817190 | Sep 2019 → Sep 2020 | atopic eczema | DS Biopharma | Terminated | Missed primary |
| Phase 2 | NCT02864498 | Jan 2017 → Jun 2018 | atopic eczema | DS Biopharma | Completed | Missed primary |
| Phase 2 | NCT02925793 | Dec 2016 → Jul 2018 | atopic eczema | DS Biopharma | Completed | No outcome recorded |
| Phase 2 | NCT02211417 | Jan → Nov 2015 | atopic eczema | Dignity Sciences Ltd. | Completed | Missed primary |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIHOMO-GAMMA-LINOLENIC ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | .gamma.-homolinolenic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | 20:3 (.omega.-6) fatty acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | 20:3(N-6) | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | 8z,11z,14z-eicosatrienoic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | Bishomo-.gamma.-linolenic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | Cis-8,11,14-eicosatrienoicacid | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | Daleuton | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | Diroleuton | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | DS-107G | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Known as | DS107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864498 ↗ |
| Known as | RO 12-1989 | ChEMBL registry synonym — accepted as the source's own label CHEMBL465183 ↗ |
| Modality | Small molecule | — CHEMBL465183 ↗ |
| Route | Oral | “Oral DS107 (2 g) will be orally administered for 8 weeks, and will be compared against placebo.” NCT02211417 ↗ |